Industry
Biotechnology
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
May 13, 2024 | 8:41 pm
Portfolio Pulse from Benzinga Newsdesk
May 08, 2024 | 10:16 am
Portfolio Pulse from Benzinga Newsdesk
April 03, 2024 | 3:35 pm
Portfolio Pulse from Benzinga Newsdesk
April 03, 2024 | 2:06 pm
Portfolio Pulse from Benzinga Newsdesk
April 03, 2024 | 1:32 pm
Portfolio Pulse from Benzinga Newsdesk
April 03, 2024 | 12:23 pm
Portfolio Pulse from Henry Khederian
April 02, 2024 | 4:46 pm
Portfolio Pulse from Benzinga Newsdesk
April 02, 2024 | 10:22 am
Portfolio Pulse from Benzinga Newsdesk
April 02, 2024 | 5:49 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.